Skip to main content

Table 2 Cost estimates and AE incidences

From: Cost-effectiveness analysis of FOLFOX4 and sorafenib for the treatment of advanced hepatocellular carcinoma in China

 

Unit cost (US$)

Recommended dosage/frequency

Cost per month (30 days)

Drug therapy costs

 Sorafenib

1888 (60a 200 mg)

400 mg twice per day

3777

 FOLFOX4

 

≈ 2.14 treatment cycles per month

1865

  Oxaliplatin

290 (50 mg)

138 mg per cycle

1716

  5 FU

8 (400 mg)

3247 mg per cycle

132

  LV

16 (1225 mg)

649 mg per cycle

18

 

Unit cost (US$)

Incidence

Sorafenib

FOLFOX4

Other medical costs

 General warda

8/day

/

5 days per cycle

 Testsb

155/set

Once per month

Once per cycle

 Adverse event

Cost/event

  

  Nausea + vomiting

65

11.4%

41.0%

 Abnormal

  AST/ALT values

59

0.0%

31.7%

  Alopecia

0

24.8%

0.0%

  Anorexia

26

12.8%

26.8%

  Bilirubin

349

0.0%

20.2%

  Fatigue

3

20.1%

17.5%

  Diarrhea

13

25.5%

15.9%

  Sensory neuropathy

3

0.0%

15.3%

  HFSR

4

45.0%

0.0%

  Rash

7

20.1%

0.0%

  Hypertension

37

18.8%

0.0%

  Bone marrow suppression

79

0.0%

68.9%

  1. aOnly the hospitalization bed fee was counted, as other medical costs during hospitalization have been considered in the model
  2. bTests included abdominal ultrasound, MRI, hematological examination, and liver and kidney function. The tests with similar frequency for the two therapies were not included, e.g., TC tests with costs of US$ 310, which were performed once bi-monthly for each therapy